Literature DB >> 27009425

Induced pluripotent stem cells: at the heart of cardiovascular precision medicine.

Ian Y Chen1,2, Elena Matsa2, Joseph C Wu1,2,3.   

Abstract

The advent of human induced pluripotent stem cell (hiPSC) technology has revitalized the efforts in the past decade to realize more fully the potential of human embryonic stem cells for scientific research. Adding to the possibility of generating an unlimited amount of any cell type of interest, hiPSC technology now enables the derivation of cells with patient-specific phenotypes. Given the introduction and implementation of the large-scale Precision Medicine Initiative, hiPSC technology will undoubtedly have a vital role in the advancement of cardiovascular research and medicine. In this Review, we summarize the progress that has been made in the field of hiPSC technology, with particular emphasis on cardiovascular disease modelling and drug development. The growing roles of hiPSC technology in the practice of precision medicine will also be discussed.

Entities:  

Mesh：

Year:  2016        PMID： 27009425      PMCID： PMC5917945          DOI： 10.1038/nrcardio.2016.36

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  175 in total

1.  Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells.

Authors:  Daniel Paull; Ana Sevilla; Hongyan Zhou; Aana Kim Hahn; Hesed Kim; Christopher Napolitano; Alexander Tsankov; Linshan Shang; Katie Krumholz; Premlatha Jagadeesan; Chris M Woodard; Bruce Sun; Thierry Vilboux; Matthew Zimmer; Eliana Forero; Dorota N Moroziewicz; Hector Martinez; May Christine V Malicdan; Keren A Weiss; Lauren B Vensand; Carmen R Dusenberry; Hannah Polus; Karla Therese L Sy; David J Kahler; William A Gahl; Susan L Solomon; Stephen Chang; Alexander Meissner; Kevin Eggan; Scott A Noggle
Journal:  Nat Methods       Date:  2015-08-03       Impact factor: 28.547

Review 2.  Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Karim Sallam; Yingxin Li; Philip T Sager; Steven R Houser; Joseph C Wu
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

Review 3.  A guide to genome engineering with programmable nucleases.

Authors:  Hyongbum Kim; Jin-Soo Kim
Journal:  Nat Rev Genet       Date:  2014-04-02       Impact factor: 53.242

4.  Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499.

Authors:  Kitchener D Wilson; Shijun Hu; Shivkumar Venkatasubrahmanyam; Ji-Dong Fu; Ning Sun; Oscar J Abilez; Joshua J A Baugh; Fangjun Jia; Zhumur Ghosh; Ronald A Li; Atul J Butte; Joseph C Wu
Journal:  Circ Cardiovasc Genet       Date:  2010-08-23

5.  Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes.

Authors:  Shugo Tohyama; Fumiyuki Hattori; Motoaki Sano; Takako Hishiki; Yoshiko Nagahata; Tomomi Matsuura; Hisayuki Hashimoto; Tomoyuki Suzuki; Hiromi Yamashita; Yusuke Satoh; Toru Egashira; Tomohisa Seki; Naoto Muraoka; Hiroyuki Yamakawa; Yasuyuki Ohgino; Tomofumi Tanaka; Masatoshi Yoichi; Shinsuke Yuasa; Mitsushige Murata; Makoto Suematsu; Keiichi Fukuda
Journal:  Cell Stem Cell       Date:  2012-11-15       Impact factor: 24.633

Review 6.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

Review 7.  Heart valve development: regulatory networks in development and disease.

Authors:  Michelle D Combs; Katherine E Yutzey
Journal:  Circ Res       Date:  2009-08-28       Impact factor: 17.367

8.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts.

Authors:  Michael A Laflamme; Kent Y Chen; Anna V Naumova; Veronica Muskheli; James A Fugate; Sarah K Dupras; Hans Reinecke; Chunhui Xu; Mohammad Hassanipour; Shailaja Police; Chris O'Sullivan; Lila Collins; Yinhong Chen; Elina Minami; Edward A Gill; Shuichi Ueno; Chun Yuan; Joseph Gold; Charles E Murry
Journal:  Nat Biotechnol       Date:  2007-08-26       Impact factor: 54.908

9.  Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.

Authors:  Elena Matsa; Divya Rajamohan; Emily Dick; Lorraine Young; Ian Mellor; Andrew Staniforth; Chris Denning
Journal:  Eur Heart J       Date:  2011-03-02       Impact factor: 29.983

10.  piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells.

Authors:  Knut Woltjen; Iacovos P Michael; Paria Mohseni; Ridham Desai; Maria Mileikovsky; Riikka Hämäläinen; Rebecca Cowling; Wei Wang; Pentao Liu; Marina Gertsenstein; Keisuke Kaji; Hoon-Ki Sung; Andras Nagy
Journal:  Nature       Date:  2009-03-01       Impact factor: 49.962
View more
  80 in total

1.  Patient-Specific Induced Pluripotent Stem Cell-Based Disease Model for Pathogenesis Studies and Clinical Pharmacotherapy.

Authors:  Yingxin Li; Karim Sallam; Peter J Schwartz; Joseph C Wu
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-06

2.  [Leukocyte count of puerperal sows].

Authors:  D Mäde; G Wujanz
Journal:  Berl Munch Tierarztl Wochenschr       Date:  1996-09       Impact factor: 0.328

Review 3.  Intensive care for human hearts in pluripotent stem cell models.

Authors:  Pelin Golforoush; Michael D Schneider
Journal:  NPJ Regen Med       Date:  2020-03-06

4.  Expandable progenitors from induced pluripotent stem cells.

Authors:  Shigeo Masuda; Shigeru Miyagawa; Satsuki Fukushima; Terumi Nakamura; Maaz Asher Khurram; Tsuyoshi Ishikawa; Atsuhiro Saito; Yoshiki Sawa
Journal:  Nat Rev Cardiol       Date:  2016-08-19       Impact factor: 32.419

5.  Alternative approaches to generating cardiomyocytes are under development.

Authors:  Ian Y Chen; Elena Matsa; Joseph C Wu
Journal:  Nat Rev Cardiol       Date:  2016-08-19       Impact factor: 32.419

Review 6.  Screening out irrelevant cell-based models of disease.

Authors:  Peter Horvath; Nathalie Aulner; Marc Bickle; Anthony M Davies; Elaine Del Nery; Daniel Ebner; Maria C Montoya; Päivi Östling; Vilja Pietiäinen; Leo S Price; Spencer L Shorte; Gerardo Turcatti; Carina von Schantz; Neil O Carragher
Journal:  Nat Rev Drug Discov       Date:  2016-09-12       Impact factor: 84.694

7.  Cardiac subtype characterization using all-optical action potential imaging.

Authors:  Praveen Shukla; Joseph C Wu
Journal:  Eur Heart J       Date:  2017-01-21       Impact factor: 29.983

8.  Induced pluripotent stem cells as a biopharmaceutical factory for extracellular vesicles.

Authors:  Masataka Nishiga; Hongchao Guo; Joseph C Wu
Journal:  Eur Heart J       Date:  2018-05-21       Impact factor: 29.983

Review 9.  Molecular mechanisms underlying cardiotoxicity of novel cancer therapeutics.

Authors:  Simon Braumann; Stephan Baldus; Roman Pfister
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

10.  CRISPRi/a Screening with Human iPSCs.

Authors:  Masataka Nishiga; Lei S Qi; Joseph C Wu
Journal:  Methods Mol Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.